Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of JAR-2203 in Healthy Participants With Elevated Plasma Lipoprotein(a) (JAR2203-SAD-P1)

A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Administration of JAR-2203 in Healthy Participants

This first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and effects on Lp(a) of single ascending doses of JAR-2203 in healthy adults with elevated Lp(a).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

JAR-2203 is an investigational small interfering RNA (siRNA) targeting LPA mRNA to reduce plasma lipoprotein(a) [Lp(a)] levels. This first-in-human, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of JAR-2203 in healthy participants with elevated Lp(a). Approximately 44 participants will be enrolled across six sequential dose cohorts, with dose escalation based on review by a Safety Review Committee.

Study Type

Interventional

Enrollment (Estimated)

44

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100070
        • Recruiting
        • Beijing Tiantan Hospital, Capital Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Healthy adult male or female participants aged 18-60 years (inclusive) at the time of signing the informed consent form (ICF).
  • At screening, male participants must have a body weight ≥ 50 kg, female participants must have a body weight ≥ 45 kg, and body mass index (BMI) must be 18-28 kg/m² (inclusive).
  • At screening, lipoprotein(a) [Lp(a)] ≥ 30 mg/dL.
  • Male participants and female participants of childbearing potential must agree to use highly effective contraceptive measures throughout the entire study period. Male participants must have no plan to donate sperm; female participants of childbearing potential must have no plan to become pregnant, donate eggs, or undergo oocyte cryopreservation. Female participants must not have had unprotected sexual intercourse within 14 days before screening.
  • Voluntarily sign the ICF and be able to comply with the relevant study requirements and all restrictions during the study period.

Exclusion Criteria:

  • History of clinically significant diseases involving the neuropsychiatric, cardiovascular, respiratory, gastrointestinal, urinary, endocrine/metabolic, immune, musculoskeletal, or hematologic systems, as judged by the investigator.
  • Any clinically significant abnormal findings on physical examination, vital signs, ECG, or laboratory tests, as judged by the investigator.
  • Systolic blood pressure ≥ 140 mmHg or < 90 mmHg, or diastolic blood pressure ≥ 90 mmHg or < 50 mmHg.
  • Fridericia-corrected QT interval (QTcF) > 450 ms.
  • Positive serological results for HBV, HCV antibody (HCV-Ab), HIV antibody (HIV-Ab), or Treponema pallidum antibody (Anti-TP). HBV positivity is defined as either (1) positive HBsAg or (2) positive HBcAb with negative HBsAb.
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > upper limit of normal (ULN); gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), or total bilirubin (TBiL) > 1.5 × ULN.
  • Estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73 m².
  • Total cholesterol (TC) or low-density lipoprotein cholesterol (LDL-C) > 1.2 × ULN; triglycerides (TG) > 2.3 mmol/L.
  • History of clinically significant hypersensitivity, intolerance, or allergic reactions to any drugs, oligonucleotides, foods, or other substances, as judged by the investigator.
  • Acute febrile illness or evidence of active infection within 7 days prior to screening.
  • Administration of any medicinal product within 14 days prior to screening that, in the investigator's judgment, may potentially affect the evaluation outcomes of this study.
  • Receipt of any live vaccine within 1 month before screening, or planned receipt of any live vaccine during the study period.
  • Any surgery within 12 months prior to screening, or planned surgery during the study period.
  • History of alcohol or drug abuse within 1 month prior to screening that, in the investigator's judgment, may potentially affect the evaluation outcomes of this study (alcohol consumption > 14 units/week; 1 unit of alcohol = 350 mL of beer, 150 mL of wine, or 30 mL of spirits).
  • Positive result on breath alcohol test, urine cotinine test, or urine drug screen at screening.
  • Participation as a subject in any pharmaceutical clinical trial within 3 months prior to screening; receipt of any siRNA therapy within 12 months prior to screening; or receipt of any antisense oligonucleotide therapy within 6 months prior to screening.
  • Blood loss or blood donation ≥ 400 mL, or donation of blood products ≥ 2 units, within 3 months prior to screening.
  • Unwilling to abstain from smoking, alcohol consumption, caffeine-containing foods or beverages, strenuous exercise, or other behaviors that may affect drug absorption, distribution, metabolism, and excretion from 24 hours prior to dosing throughout the entire study period.
  • Pregnant or lactating female participants; female participants of childbearing potential with a positive serum HCG test prior to dosing; or participants of reproductive potential who are unable or unwilling to use investigator-approved contraceptive measures throughout the entire study period as instructed by the investigator.
  • History of intolerance to subcutaneous injection, or presence of scars (e.g., surgical or burn scars) at the planned subcutaneous administration site.
  • Poor peripheral venous access.
  • Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this clinical study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: JAR-2203

Participants who receive a single subcutaneous injection of JAR-2203.

JAR-2203 solution for injection given as a single subcutaneous injection; planned dose levels are 7.5, 30, 75, 150, 225, and 300 mg.

Placebo Comparator: Placebo

Participants who receive a single subcutaneous injection of placebo.

Placebo for injection given as a single subcutaneous injection at a volume matched to the active treatment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
Time Frame: From first dose until the end of the study (through Day 169).

An adverse event is any untoward medical occurrence in a clinical trial participant. A TEAE is any event with onset after administration of the first dose of investigational product and up to and including the end of the study. Clinically significant changes in vital signs, 12-lead electrocardiograms (ECGs), and safety laboratory analytes are included as TEAEs. Severity is graded using NCI-CTCAE v6.0.

From first dose until the end of the study (through Day 169).

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maximum Observed Concentration (Cmax) of JAR-2203
Time Frame: Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

Plasma concentrations of JAR-2203 will be measured.

Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.
Time to Reach Maximum Concentration (Tmax) of JAR-2203
Time Frame: Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

Plasma concentrations of JAR-2203 will be measured.

Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.
Terminal Elimination Half-life (t1/2) of JAR-2203
Time Frame: Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

Plasma concentrations of JAR-2203 will be measured.

Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.
Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC0-24h) of JAR-2203
Time Frame: Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

Plasma concentrations of JAR-2203 will be measured.

Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.
Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) of JAR-2203
Time Frame: Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

Plasma concentrations of JAR-2203 will be measured.

Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.
Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of JAR-2203
Time Frame: Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

Plasma concentrations of JAR-2203 will be measured.

Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.
Apparent Total Clearance (CL/F) of JAR-2203
Time Frame: Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

Plasma concentrations of JAR-2203 will be measured.

Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.
Apparent Volume of Distribution (Vz/F) of JAR-2203
Time Frame: Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

Plasma concentrations of JAR-2203 will be measured.

Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.
Urinary Excretion Parameters of JAR-2203 (Cohort 5 only)
Time Frame: Predose and at 0-6, 6-12,12-24 and 24-48(Day 2) hours postdose

Cumulative amount excreted in urine (Ae), cumulative fraction excreted in urine (Fe), and renal clearance (CLR).

Predose and at 0-6, 6-12,12-24 and 24-48(Day 2) hours postdose
Change From Baseline in Plasma Lipoprotein(a) [Lp(a)] Levels
Time Frame: Predose (within 60 minutes before dosing), at 12, 24 (Day 2), and 48 (Day 3) hours postdose, and at Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169.

Change from baseline in plasma Lp(a) by cohort and scheduled time points.

Predose (within 60 minutes before dosing), at 12, 24 (Day 2), and 48 (Day 3) hours postdose, and at Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169.
Percent Change From Baseline in Plasma Lipoprotein(a) [Lp(a)] Levels
Time Frame: Predose (within 60 minutes before dosing), at 12, 24 (Day 2), and 48 (Day 3) hours postdose, and at Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169.

Percent change from baseline in plasma Lp(a) by cohort and scheduled time points.

Predose (within 60 minutes before dosing), at 12, 24 (Day 2), and 48 (Day 3) hours postdose, and at Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169.
Change From Baseline in Other Lipid and Lipoprotein Parameters
Time Frame: Predose (within 60 minutes before dosing), at 12, 24 (Day 2), and 48 (Day 3) hours postdose, and at Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169.

Change from baseline in total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and triglycerides (TG).

Predose (within 60 minutes before dosing), at 12, 24 (Day 2), and 48 (Day 3) hours postdose, and at Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Immunogenicity
Time Frame: Predose (within 60 minutes before dosing) and at Days 15, 29, and 57.

Incidence of anti-drug antibodies (ADA) and, if applicable, neutralizing antibodies (NAb).

Predose (within 60 minutes before dosing) and at Days 15, 29, and 57.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 19, 2026

Primary Completion (Estimated)

July 30, 2027

Study Completion (Estimated)

November 30, 2027

Study Registration Dates

First Submitted

November 8, 2026

First Submitted That Met QC Criteria

November 8, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 8, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • JAR-2203-1001
  • ChiCTR2600134394 (Other Identifier: Chinese Clinical Trial Registry)
  • 2026LP02024 (Other Identifier: National Medical Products Administration, China)
  • CTR20263460 (Other Identifier: Center for Drug Evaluation, NMPA, China)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data (IPD) from this study will not be shared. This is an early-phase study in a small number of healthy participants, and the sponsor does not expect the limited participant-level data to provide meaningful additional scientific value beyond the aggregated results that will be reported. The data also contain proprietary information regarding an investigational product.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.